Please login to the form below

Procoralan

This page shows the latest Procoralan news and features for those working in and with pharma, biotech and healthcare.

The drug has been marketed for years in Europe by privately-held Servier under the Procoralan brand name.

FDA clears Amgen's Corlaner for heart failure

Corlaner is already on the market in Europe - where it is sold by privately held Servier as Procoralan and was approved to treat stable angina in 2005 and CHF in 2012.
Amgen gets priority review for chronic heart failure hope

require additional clinical trials, despite the fact that the drug is already sold (as Servier's Procoralan) for CHF and also stable angina in Europe.
Amgen throws its hat into the cholesterol antibody ring

Procoralan (ivabradine) from Servier in July.
Amgen drug misses endpoint in acute heart failure trial

This was part of a deal that involved Amgen obtaining US rights to Servier's chronic heart failure drug Procoralan (ivabradine).
Amgen buys US rights to Servier’s Procoralan

Amgen buys US rights to Servier’ s Procoralan. Also obtains option to develop S38844 while Servier has option to commercialise omecamtiv mecarbil in Europe. ... The major drug involved in the deal is Servier's Procoralan (ivabradine), which Amgen has

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Heart failure therapy embarks on a new era

has been sold for HF in Europe as Procoralan/Corlenter by originator Servier since 2012.
Deal Watch table for July 2013

100. ‡‡ Servier / Amgen . Cardiovascular collaboration, licence and option. Procoralan (ivabradine, approved), S38844 (p2), omecamtiv mecarbil (p2).
Pharma deals during July 2013

Under this agreement, Servier has granted Amgen US rights to Procoralan (ivabradine), which is approved in Europe for chronic heart failure and stable angina in patients with elevated heart rates. ... Amgen is paying $50m upfront for US rights to

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Home based, Editorial Team Leader, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Add my company

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....